荣昌生物以3亿元闲置自有资金购买浦发银行36天结构性存款，属例行现金管理

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility
for the contents of this announcement, make no representation as to its accuracy or completeness and expressly
disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the
contents of this announcement.

RemeGen Co., Ltd.*
榮昌生物製藥(煙台)股份有限公司

(A joint stock company incorporated in the People ’s Republic of China with limited liability)

(Stock Code: 9995)

DISCLOSABLE TRANSACTION
PURCHASE OF WEALTH MANAGEMENT PRODUCTS
PURCHASE OF WEALTH MANAGEMENT PRODUCTS
At the 36th meeting held by the second session of the Board on March 27, 2026, (1) a resolution
regarding cash management using self-owned funds was considered and approved, pursuant to
which the Company may purchase wealth management products using part of idle self-owned
funds of not more than RMB2,500.0 million; and (2) a resolution regarding cash management
using idle raised proceeds was considered and approved, pursuant to which the Company may
purchase principal-guaranteed wealth management products using part of idle raised proceeds
from A shares of not more than RMB80.0 million.
As disclosed in the announcements of the Company dated May 13, 2026 and July 2, 2026, (1)
on May 6, 2026, the Company entered into the SPDB Wealth Management Product Agreement
No. 5 with SPDB Yantai Branch, pursuant to which the Company agreed to purchase wealth
management product of an amount of RMB200.0 million from SPDB Yantai Branch using
idle self-owned funds; (2) on May 13, 2026, the Company entered into the SPDB Wealth
Management Product Agreement No. 7 with SPDB Yantai Branch, pursuant to which the
Company agreed to purchase wealth management product of an amount of RMB100.0 million
from SPDB Yantai Branch using idle self-owned funds; and (3) on July 2, 2026, the Company
entered into the SPDB Wealth Management Product Agreement No. 9 with SPDB Yantai Branch,
pursuant to which the Company agreed to purchase wealth management product of an amount of
RMB80.0 million from SPDB Yantai Branch using idle raised proceeds.
The Board announces that, on September 2, 2026, the Company further entered into the SPDB
Wealth Management Product Agreement No. 11 with SPDB Yantai Branch, pursuant to which
the Company agreed to purchase wealth management product of an amount of RMB300.0 million
from SPDB Yantai Branch using idle self-owned funds.

1

LISTING RULES IMPLICATIONS
As the Company entered into (1) the SPDB Wealth Management Product Agreement No. 5 with
SPDB Yantai Branch on May 6, 2026, (2) the SPDB Wealth Management Product Agreement
No. 7 with SPDB Yantai Branch on May 13, 2026, and (3) the SPDB Wealth Management
Product Agreement No. 9 with SPDB Yantai Branch on July 2, 2026, and still holds the wealth
management products under such agreements, and the transactions contemplated under (1)
the SPDB Wealth Management Product Agreement No. 5, (2) the SPDB Wealth Management
Product Agreement No. 7, (3) the SPDB Wealth Management Product Agreement No. 9 and (4)
the SPDB Wealth Management Product Agreement No. 11 are conducted with the same bank
and are of similar nature within a 12-month period, for the purpose of calculating the relevant
percentage ratios under Rule 14.22 of the Listing Rules, these transactions shall be aggregated in
each case as if they were one transaction with the said bank.
As one of the applicable percentage ratios (as defined under Rule 14.07 of the Listing Rules)
in respect of the SPDB Wealth Management Product Agreements exceeds 5% but all of the
applicable percentage ratios are less than 25%, the purchase of wealth management products
under the SPDB Wealth Management Product Agreements therefore constitutes a discloseable
transaction of the Company under Chapter 14 of the Listing Rules and is subject to the reporting
and announcement requirements under the Listing Rules.
BACKGROUND
On May 6, 2026, the Company entered into the SPDB Wealth Management Product Agreement
No. 5 with SPDB Yantai Branch, pursuant to which the Company agreed to purchase wealth
management product of an amount of RMB200.0 million from SPDB Yantai Branch using idle
self-owned funds.
On May 13, 2026, the Company entered into the SPDB Wealth Management Product Agreement
No. 7 with SPDB Yantai Branch, pursuant to which the Company agreed to purchase wealth
management product of an amount of RMB100.0 million from SPDB Yantai Branch using idle
self-owned funds.
On July 2, 2026, the Company entered into the SPDB Wealth Management Product Agreement
No. 9 with SPDB Yantai Branch, pursuant to which the Company agreed to purchase wealth
management product of an amount of RMB80.0 million from SPDB Yantai Branch using idle
raised proceeds.
The Board announces that, on September 2, 2026, the Company further entered into the SPDB
Wealth Management Product Agreement No. 11 with SPDB Yantai Branch, pursuant to which the
Company agreed to purchase wealth management product of an amount of RMB300.0 million from
SPDB Yantai Branch using idle self-owned funds.

2

SPDB WEALTH MANAGEMENT PRODUCT AGREEMENT NO. 11
The principal terms of the SPDB Wealth Management Product Agreement No. 11 are set out as
follows:
Name of product

:

Liduoduo Corporate Stable Profit 99JG3242 (Three-Tier Bullish)
RMB Corporate Structured Deposit (利多多公司穩利 99JG3242
期(三層看漲)人民幣對公結構性存款)

Type of product

:

Principal-guaranteed with floating income

Linked target

:

EUR-USD exchange rate

Principal amount

:

RMB300.0 million

Validity period of product

:

36 days

Effective date of product

:

September 2, 2026

Expiry date of product

:

October 8, 2026

Expected annualized
yield rate

:

0.7% or 1.75% or 1.95%

Right of early termination

:

SPDB Yantai Branch has the right to early terminate the
agreement.

Investment scope

:

The proceeds from the sales of this structured deposit product
will be nominal principal, the capital costs of which will be used
to enter into transactions with counterparty to make investment
in financial derivatives linked to the counterparty’s investment
income and the EUR-USD spot rate.

The terms of the SPDB Wealth Management Product Agreement No.11 were determined upon
arm’s length negotiations between the parties.
INFORMATION ON THE PARTIES
The Company is a commercial-ready biopharmaceutical company committed to the discovery,
development and commercialization of innovative and differentiated biologics for the treatment of
autoimmune, oncology and ophthalmic diseases with unmet medical needs in China and globally.
SPDB is a bank incorporated in the PRC, the shares of which are listed on the Shanghai Stock
Exchange (stock code: 600000). The principal businesses of SPDB are providing corporate and
personal banking services, conducting treasury business, and providing asset management and
other financial services. SPDB Yantai Branch is a branch of SPDB.
To the best knowledge, information and belief of the Directors having made all reasonable
enquiries, SPDB Yantai Branch, SPDB and their ultimate substantial beneficial owners as publicly
disclosed by SPDB are third parties independent from the Company and its connected persons.

3

REASONS AND BENEFITS FOR ENTERING INTO THE SPDB WEALTH MANAGEMENT
PRODUCT AGREEMENT NO.11
On the premise of strictly controlling investment risks, the Company intends to fully revitalize idle
self-owned funds and improve capital utilization efficiency by deploying and managing idle funds
through bank wealth management products. The allocated low-to-medium risk products feature
overall controllable risks and yields higher than those of bank time deposits for the same period,
which can effectively boost the investment returns on idle funds.
The Directors consider that the terms of the SPDB Wealth Management Product Agreement No.11
and the transactions contemplated thereunder are fair and reasonable, on normal commercial terms
or better in the ordinary course of business of the Group, and are in the interests of the Company
and its Shareholders as a whole.
LISTING RULES IMPLICATIONS
As the Company entered into (1) the SPDB Wealth Management Product Agreement No. 5 with
SPDB Yantai Branch on May 6, 2026, (2) the SPDB Wealth Management Product Agreement
No. 7 with SPDB Yantai Branch on May 13, 2026, and (3) the SPDB Wealth Management
Product Agreement No. 9 with SPDB Yantai Branch on July 2, 2026, and still holds the wealth
management products under such agreements, and the transactions contemplated under (1) the
SPDB Wealth Management Product Agreement No. 5, (2) the SPDB Wealth Management Product
Agreement No. 7, (3) the SPDB Wealth Management Product Agreement No. 9 and (4) the SPDB
Wealth Management Product Agreement No. 11 are conducted with the same bank and are of
similar nature within a 12-month period, for the purpose of calculating the relevant percentage
ratios under Rule 14.22 of the Listing Rules, these transactions shall be aggregated in each case as
if they were one transaction with the said bank.
As one of the applicable percentage ratios (as defined under Rule 14.07 of the Listing Rules) in
respect of the SPDB Wealth Management Product Agreements exceeds 5% but all of the applicable
percentage ratios are less than 25%, the purchase of wealth management products under the SPDB
Wealth Management Product Agreements therefore constitutes a discloseable transaction of the
Company under Chapter 14 of the Listing Rules and is subject to the reporting and announcement
requirements under the Listing Rules.

4

DEFINITIONS
Unless the context otherwise requires, the following terms used herein have the following
meanings:
“Board”

the board of Directors

“Company”

RemeGen Co., Ltd.* (榮昌生物製藥(煙台)股份有限公司), a joint
stock company incorporated in the PRC with limited liability,
the H shares and A shares of which are listed on the Main Board
of the Stock Exchange (stock code: 9995) and the Science and
Technology Innovation Board of the Shanghai Stock Exchange
(stock code: 688331), respectively

“connected person”

has the meaning ascribed to it under the Listing Rules

“Director(s)”

the director(s) of the Company

“EUR”

Euro, the lawful currency of the European Union

“Group”

the Company and its subsidiaries

“Hong Kong”

the Hong Kong Special Administrative Region of the People’s
Republic of China

“Listing Rules”

the Rules Governing the Listing of Securities on the Stock
Exchange

“PRC” or “China”

the People’s Republic of China excluding, for the purpose of this
announcement, Hong Kong, the Macau Special Administrative
Region of the People’s Republic of China and Taiwan

“RMB”

Renminbi, the lawful currency of the PRC

“Shareholder(s)”

holder(s) of the shares of the Company

“SPDB”

Shanghai Pudong Development Bank Co., Ltd., a bank
incorporated in the PRC

“SPDB Wealth Management
Product Agreements”

SPDB Wealth Management Product Agreement No. 5, SPDB
Wealth Management Product Agreement No. 7, SPDB Wealth
Management Product Agreement No. 9, and SPDB Wealth
Management Product Agreement No. 11

“SPDB Wealth Management
Product Agreement No. 5”

the wealth management product agreement entered into between
the Company and SPDB Yantai Branch dated May 6, 2026 in
relation to the purchase of wealth management product in the
amount of RMB200.0 million

5

“SPDB Wealth Management
Product Agreement No. 7”

the wealth management product agreement entered into between
the Company and SPDB Yantai Branch dated May 13, 2026 in
relation to the purchase of wealth management product in the
amount of RMB100.0 million

“SPDB Wealth Management
Product Agreement No. 9”

the wealth management product agreement entered into between
the Company and SPDB Yantai Branch dated July 2, 2026 in
relation to the purchase of wealth management product in the
amount of RMB80.0 million

“SPDB Wealth Management
Product Agreement No. 11”

the wealth management product agreement entered into between
the Company and SPDB Yantai Branch dated September 2, 2026
in relation to the purchase of wealth management product in the
amount of RMB300.0 million

“SPDB Yantai Branch”

Yantai Branch of Shanghai Pudong Development Bank Co., Ltd.

“Stock Exchange”

The Stock Exchange of Hong Kong Limited

“USD”

United States dollar, the lawful currency of the United States of
America

“%”

percent
By order of the Board
RemeGen Co., Ltd.*
Mr. Wang Weidong
Chairman and Executive Director

Yantai, the PRC
September 2, 2026

As at the date of this announcement, the Board comprises Mr. Wang Weidong, Dr. Fang Jianmin,
Mr. Wen Qingkai, Ms. Fang Michelle Yi and Mr. Wang Yuxiao as the executive Directors, Dr.
Wang Liqiang as the non-executive Director, and Mr. Song Xiliang, Mr. Huang Guobin and Mr.
Chen Yunjin as the independent non-executive Directors.
*

For identification purpose only

6

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性
或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因依賴該等
內容而引致的任何損失承擔任何責任。

RemeGen Co., Ltd.*
榮 昌 生 物 製 藥（ 煙 台 ）股 份 有 限 公 司
（於中華人民共和國註冊成立的股份有限公司）

（股份代號：9995）

須予披露交易
購買理財產品
購買理財產品
本公司第二屆董事會第三十六次會議已於2026 年3 月27 日，(1)審議批准了關
於使用自有資金進行現金管理的決議，根據該決議本公司可使用不超過人民幣
2,500.0 百萬元額度的部分閒置自有資金購買理財產品；及(2)審議批准了關於
使用閒置募集資金進行現金管理的決議，根據該決議本公司可使用不超過人民
幣80.0百萬元額度的部分閒置A股募集資金購買保本型銀行理財產品。
誠如本公司日期為2026年5月13日及2026年7月2日的公告披露，(1)於2026年5
月6日，本公司與浦發銀行煙台分行訂立浦發銀行理財產品5號協議，據此本公
司同意以人民幣200.0 百萬元的閒置自有資金向浦發銀行煙台分行購買理財產
品；(2)於2026年5月13日，本公司與浦發銀行煙台分行訂立浦發銀行理財產品
7號協議，據此本公司同意以人民幣100.0百萬元的閒置自有資金向浦發銀行煙
台分行購買理財產品；及(3)於2026年7月2日，本公司與浦發銀行煙台分行訂
立浦發銀行理財產品9 號協議，據此本公司同意以人民幣80.0 百萬元的閒置募
集資金向浦發銀行煙台分行購買理財產品。
董事會宣佈，於2026年9月2日，本公司進一步與浦發銀行煙台分行訂立浦發銀
行理財產品11號協議，據此本公司同意以人民幣300.0百萬元的閒置自有資金
向浦發銀行煙台分行購買理財產品。

1

上市規則的涵義
由於本公司於2026年5月6日與浦發銀行煙台分行訂立了(1)浦發銀行理財產品5
號協議，於2026年5月13日與浦發銀行煙台分行訂立了(2)浦發銀行理財產品7
號協議，並於2026年7月2日與浦發銀行煙台分行訂立了(3)浦發銀行理財產品9
號協議，且仍然持有該等協議項下的理財產品，因此(1)浦發銀行理財產品5號
協議、(2)浦發銀行理財產品7號協議、(3)浦發銀行理財產品9號協議及(4)浦發
銀行理財產品11號協議項下擬進行的交易均在12個月內與同一家銀行進行且性
質相似，就根據上市規則第14.22條計算相關百分比率而言，該等交易在各情況
下將合併處理，猶如該等交易為與該銀行進行的一次交易。
根據上市規則第14.07 條計算的浦發銀行理財產品協議之適用百分比率有一項
超過5%，但所有的適用百分比率均低於25%，因此，基於浦發銀行理財產品協
議，理財產品之購買構成上市規則第14章之本公司的須予披露交易，須遵守上
市規則項下之申報及公告規定。

背景
於2026年5月6日，本公司與浦發銀行煙台分行訂立浦發銀行理財產品5號協議，
據此本公司同意以人民幣200.0百萬元的閒置自有資金向浦發銀行煙台分行購買理
財產品。
於2026年5月13日，本公司與浦發銀行煙台分行訂立浦發銀行理財產品7號協議，
據此本公司同意以人民幣100.0百萬元的閒置自有資金向浦發銀行煙台分行購買理
財產品。
於2026年7月2日，本公司與浦發銀行煙台分行訂立浦發銀行理財產品9號協議，
據此本公司同意以人民幣80.0百萬元的閒置募集資金向浦發銀行煙台分行購買理
財產品。
董事會宣佈，於2026年9月2日，本公司進一步與浦發銀行煙台分行訂立浦發銀行
理財產品11號協議，據此本公司同意以人民幣300.0百萬元的閒置自有資金向浦發
銀行煙台分行購買理財產品。

2

浦發銀行理財產品11號協議
浦發銀行理財產品11號協議之主要條款如下所述：
產品名稱

：

利多多公司穩利99JG3242期（三層看漲）人民幣對公結
構性存款

產品類型

：

保本浮動收益類

掛鈎標的

：

歐元兌美元匯率

本金金額

：

人民幣300.0百萬元

產品期限

：

36天

產品生效日期

：

2026年9月2日

產品到期日

：

2026年10月8日

預期年化收益率

：

0.7%或1.75%或1.95%

提前終止權

：

浦發銀行煙台分行有權提前終止協議。

投資範圍

：

本結構性存款銷售所匯集資金作為名義本金，並以該
名義本金的資金成本與交易對手敘作投資收益和歐元
兌美元即期匯率掛鈎的金融衍生品交易。

浦發銀行理財產品11號協議的條款乃經訂約方公平協商後釐定。

訂約方資料
本公司是一家具有商業價值的生物製藥公司，致力於在中國和全球範圍內發現、
開發和商業化用於治療自身免疫，腫瘤和眼科疾病且醫療需求未滿足的創新和差
異化生物製劑。
浦發銀行為一家在中國註冊成立的銀行，其股份於上海證券交易所（股份代號：
600000）上市。浦發銀行的主要業務為提供公司及個人銀行服務、從事資金業
務，並提供資產管理及其他金融服務。浦發銀行煙台分行是浦發銀行的分行。

3

經董事於作出一切合理查詢後所深知、全悉及確信，浦發銀行煙台分行、浦發銀
行及其最終主要實益擁有人（浦發銀行所公開披露者）為獨立於本公司及其關連人
士的第三方。

訂立浦發銀行理財產品11號協議的理由及裨益
本公司在嚴控投資風險的前提下，為充分盤活閒置自有資金、提升資金使用效
率，將閒置資金通過銀行理財進行運作與管理；所配置的中低風險產品整體風險
可控，且收益高於同期銀行定期存款，可有效提升閒置資金的投資收益。
董事認為，浦發銀行理財產品11號協議的條款及其項下擬進行的交易乃屬公平合
理，在本集團的日常業務中按一般商務條款或更佳條款進行，並且符合本公司及
其股東的整體利益。

上市規則涵義
由於本公司於2026年5月6日與浦發銀行煙台分行訂立了(1)浦發銀行理財產品5號
協議，於2026年5月13日與浦發銀行煙台分行訂立了(2)浦發銀行理財產品7號協
議，並於2026 年7 月2 日與浦發銀行煙台分行訂立了(3)浦發銀行理財產品9 號協
議，且仍然持有該等協議項下的理財產品，因此(1)浦發銀行理財產品5號協議、
(2)浦發銀行理財產品7號協議、(3)浦發銀行理財產品9號協議及(4)浦發銀行理財
產品11號協議項下擬進行的交易均在12個月內與同一家銀行進行且性質相似，就
根據上市規則第14.22 條計算相關百分比率而言，該等交易在各情況下將合併處
理，猶如該等交易為與該銀行進行的一次交易。
根據上市規則第14.07條計算的浦發銀行理財產品協議之適用百分比率有一項超過
5%，但所有的適用百分比率均低於25%，因此，基於浦發銀行理財產品協議，理
財產品之購買構成上市規則第14章之本公司的須予披露交易，須遵守上市規則項
下之申報及公告規定。

4

釋義
除文義另有所指外，下列詞彙用於本公告時具有以下涵義：
「董事會」

指

董事會

「本公司」

指

榮昌生物製藥（煙台）股份有限公司，一家於中國註
冊成立的股份有限公司，其H股和A股分別於聯交所
主板（股票代號：9995）和上海交易所科創板（股票
代號：688331）上市

「關連人士」

指

具有上市規則所賦予的涵義

「董事」

指

本公司董事

「歐元」

指

歐元，歐洲聯盟法定貨幣

「本集團」

指

本公司及其附屬公司

「香港」

指

中華人民共和國香港特別行政區

「上市規則」

指

聯交所證券上市規則

「中國」

指

中華人民共和國，就本公告而言，不包括香港、中
華人民共和國澳門特別行政區及台灣

「人民幣」

指

人民幣，中國法定貨幣

「股東」

指

本公司股東

「浦發銀行」

指

上海浦東發展銀行股份有限公司，一家在中國註冊
成立的銀行

「浦發銀行理財產品
協議」

指

浦發銀行理財產品5 號協議、浦發銀行理財產品7 號
協議、浦發銀行理財產品9號協議及浦發銀行理財產
品11號協議

「浦發銀行理財
產品5號協議」

指

本公司與浦發銀行煙台分行於2026年5月6日就購買
人民幣200.0百萬元理財產品簽訂的理財產品協議
5

「浦發銀行理財
產品7號協議」

指

本公司與浦發銀行煙台分行於2026 年5 月13 日就購
買人民幣100.0百萬元理財產品簽訂的理財產品協議

「浦發銀行理財
產品9號協議」

指

本公司與浦發銀行煙台分行於2026年7月2日就購買
人民幣80.0百萬元理財產品簽訂的理財產品協議

「浦發銀行理財
產品11號協議」

指

本公司與浦發銀行煙台分行於2026年9月2日就購買
人民幣300.0百萬元理財產品簽訂的理財產品協議

「浦發銀行煙台分行」 指

上海浦東發展銀行股份有限公司煙台分行

「聯交所」

指

香港聯合交易所有限公司

「美元」

指

美元，美利堅合眾國法定貨幣

「%」

指

百分比
承董事會命
榮昌生物製藥（煙台）股份有限公司
董事長兼執行董事
王威東先生

中國煙台
2026年9月2日

於本公告日期，董事會成員包括執行董事王威東先生、房健民博士、溫慶凱先
生、房藝女士及王玉曉先生；非執行董事王荔強博士；及獨立非執行董事宋希亮
先生、黃國濱先生及陳雲金先生。
* 僅供識別

6